Navigation Links
GEN reports on recent progress in Alzheimer's research

New Rochelle, NY, August 7, 2012The global market value of Alzheimer's disease therapeutics could soar to the $8 billion range once therapeutics are approved that actually change the course of the disease, reports Genetic Engineering & Biotechnology News (GEN). The current therapeutic market is valued at $3 to $4 billion, shared among drugs that temporarily delay disease progression or address the symptoms but do not alter the underlying disease, according to a recent issue of GEN.

"Despite all the research on amyloid plaques and neurofibrillary tangles there is still a debate on whether these biological phenomena are causative or symptomatic of Alzheimer's," said John Sterling, Editor-in-Chief of GEN. "Once scientists can clearly and unequivocally define key factors related to the actual biology of the disease itself, therapeutic advances could take place much more quickly."

More than 150 companies are working in the Alzheimer's space, including approximately 15 multinationals and 30 generics companies. A number of these firms are taking innovative approaches to tackling this extremely debilitating disease. For example, the USPTO in March granted a patent for Antisenilin, developed by Intellect Neurosciences. This therapy, which targets either end of -amyloid, is in Phase III trials.

Baxter has a Phase III program under way for Gammagard, a naturally occurring plasma-derived immunoglobulin for moderate-stage AD patients. The trial runs until February 2013. Phase II results suggest Gammagard may positively affect brain atrophy and cognition. The compound already is approved for immunodeficiency diseases.

Other companies covered in the GEN article include AstraZeneca, Roche, TransTech Pharma, Astex Pharmaceuticals, Memory Pharmaceuticals, Sanofi-Aventis, Eli Lilly, GE Healthcare Life Sciences, and Charles River Laboratories.


Contact: John Sterling
Mary Ann Liebert, Inc./Genetic Engineering News

Related biology news :

1. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
2. Aware, Inc. Reports Second Quarter 2012 Financial Results
3. GEN reports on growth of tissue engineering revenues
4. BGI reports the completed sequence of foxtail millet genome
5. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
6. Aware, Inc. Reports First Quarter 2012 Financial Results
7. From 503-million-year-old fungi to recent earthquakes: New Geology posted ahead of print
8. House funding bill will delay research progress and place new burdens on NIH
9. Guam conservation efforts progress
10. New report evaluates progress of Everglades Restoration Plan
11. Progress in Osteoporosis re-launched with new design, now invites commentary
Post Your Comments:
Related Image:
GEN reports on recent progress in Alzheimer's research
(Date:11/9/2015)... JOSE, Calif. , Nov. 9, 2015  Synaptics ... human interface solutions, today announced broader entry into the ... vehicle-specific solutions that match the pace of consumer electronics ... and biometric sensors are ideal for the automotive industry ... vehicle. Europe , ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... ... 25, 2015 , ... Jessica Richman and Zachary Apte, founders ... initial angel funding process. Now, they are paying it forward to other microbiome ... investments in the microbiome space. In this, they join other successful entrepreneurs-turned-angels ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has officially ... to represent the First–Person View (FPV) racing community. , FPV racing has exploded in ... racing and several new model aviation pilots have joined the community because of their ...
Breaking Biology Technology: